Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

40.81 -0.42 (-1.02%)
Delayed Quote Updated: 3:25 PM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
42 43 Next >
News headline image
First Wave BioPharma To Acquire ImmunogenX To Bolster Gastrointestinal-Focused Pipeline ↗
First Wave BioPharma Inc (NASDAQ: FWBI) has signed a non-binding term sheet to acquire ImmunogenX in an all-stock transaction with the combined company focused on advancing a pipeline for... 
Via Benzinga
News headline image
7 Undervalued Biotech Stocks That are Flying Under the Clinical Radar ↗
While the broader healthcare sector offers myriad opportunities, these undervalued biotech picks could offer robust upside. 
Via InvestorPlace
News headline image
It's Almost 2024: 3 Top Stocks to Buy Before the New Year ↗
You can pick these players up for a great price right now. 
Via The Motley Fool
News headline image
French Drugmaker Sanofi Secures European Medicines Agency's Positive Opinion For Sleeping Sickness Treatment ↗
Sanofi SA (NASDAQ: SNY), DNDi, and the HAT-r-ACC consortium  
Via Benzinga
News headline image
3 Stocks to Buy Before 2024 That Can Set You Up For Life ↗
These stocks are still relatively cheap, but don't expect them to stay that way for long. 
Via The Motley Fool
News headline image
Why NASDAQ:SNY provides a good dividend, while having solid fundamentals. ↗
Why SANOFI-ADR (NASDAQ:SNY) provides a good dividend, while having solid fundamentals. 
Via Chartmill
News headline image
How Is The Market Feeling About Sanofi? ↗
 
Via Benzinga
News headline image
Is NASDAQ:SNY a Good Fit for Dividend Investing? ↗
Is SANOFI-ADR (NASDAQ:SNY) a Good Fit for Dividend Investing? 
Via Chartmill
News headline image
French Pharma Giant Sanofi Drops Rare Disease Drug Pact As Federal Trade Commission Puts Antitrust Obstacle ↗
Sanofi SA (NASDAQ: SNY) said it is terminating the licensing agreement for Maze Therapeutics Inc.'s treatment for a rare genetic disorder after the Federal Trade Commission (FTC)  
Via Benzinga
News headline image
Vanda Pharmaceuticals Acquires Rights To Multiple Sclerosis Drug From Johnson & Johnson's Company ↗
Vanda Pharmaceuticals Inc (NASDAQ: VNDA) has acquired U.S. 
Via Benzinga
News headline image
Sanofi Lays Out Ambitious Plans To Bolster Its Pipeline, Highlights 12 Blockbuster Opportunities ↗
Sanofi SA (NASDAQ: SNY) says it has 12 drugs in development with a blockbus 
Via Benzinga
News headline image
IGM Biosciences Increases Focus On Autoimmune Diseases, Stops All Blood Cancer-Related Studies ↗
IGM Biosciences Inc (NASDAQ: IGMS) said it will focus on two strategic areas: treating colorectal cancer using IgM death receptor 5 (DR5) agonist antibodies and treating autoimmune diseases using IgM... 
Via Benzinga
News headline image
Merck Germany's Two Pivotal Trials Flunk In Multiple Sclerosis ↗
Merck KGaA (OTC: MKGAF) (OTC:  
Via Benzinga
News headline image
Looking Into Sanofi's Recent Short Interest ↗
 
Via Benzinga
News headline image
Don't overlook NASDAQ:SNY—it's a hidden gem with strong fundamentals and an attractive price tag. ↗
SANOFI-ADR (NASDAQ:SNY) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
Via Chartmill
News headline image
Investor Demand for Clarity Grows Amid Sanofi's Strategic R&D Shift ↗
Sanofi SA's (NASDAQ: SNY) CEO, Paul Hudson, is confronting mounting investor pressure as shareholders seek concrete details about the company's expanded R&D budget.  
Via Benzinga
News headline image
Weight Loss Drugs And Associated Suicidal Thoughts - European Drug Regulator Seeks Clarifications From Drug Makers ↗
European Medicines Agency (EMA) will request further clarifications from drugmakers of GLP-1 receptor agonists for diabetes and weight loss, including Novo Nordisk A/S's (NYSE: NVO) popular therapies... 
Via Benzinga
News headline image
Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
2 Biotech Stocks You Can Buy and Hold for the Next Decade ↗
These stocks aren't popular on the market right now, but investors shouldn't let that scare them off. 
Via The Motley Fool
News headline image
Teva Pharma is the way to play the re-rise of generic drugs
Generic and specialty pharmaceutical company, Teva Pharmaceutical's stock, has underperformed for years, but a potential spinoff may be a catalyst for growth 
Via MarketBeat
News headline image
Regeneron, Sanofi Plot A Major Expansion That Could Add $4 Billion In Future Sales ↗
Regeneron and Sanofi are partnered on Dupixent, a treatment for conditions tied to type 2 inflammation. 
Via Investor's Business Daily
News headline image
Sanofi/Regeneron's Blockbuster Prescription Drug Dupixent Shows Additional Promise In Chronic Lung Disorder ↗
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) announced the second Dupixent (dupilumab) Phase 3 chronic obstructive pulmonary disease (COPD) trial (NOTUS) showed that... 
Via Benzinga
News headline image
Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Antibody Player Dianthus Therapeutics Has Potential Amid Active M&A Landscape in Complement-Focused Firms: Analyst ↗
Wedbush initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), noting its lead program DNTH103 as a well-positioned monoclonal antibody directed against the active form of the  
Via Benzinga
News headline image
US CDC Rolls Out Additional Doses For Sanofi/AstraZeneca Recently Approved Respiratory Infection Drug As Demand Surges ↗
The U.S. 
Via Benzinga
News headline image
Major Buyout Firms Eye Sanofi's Consumer Health Division Spinoff Valued Over $20B ↗
Sanofi SA (NYSE: SNY) has reportedly initiated talks with Rothschild & Co. to explore the possibility of spinning off its consumer health division, which could potentially value the business at over... 
Via Benzinga
News headline image
Don't overlook NASDAQ:SNY—it's a hidden gem with strong fundamentals and an attractive price tag. ↗
SANOFI-ADR (NASDAQ:SNY) is an undervalued gem with solid fundamentals. 
Via Chartmill
News headline image
MarketBeat Week in Review – 11/6 - 11/10
Stocks closed the week with a strong rally, but the rally may reverse when investors get the latest information about inflation and retail stocks next week 
Via MarketBeat
Topics Artificial Intelligence Economy
News headline image
Pfizer and Sanofi shares fall, which one to scoop up?
Pharmaceutical stocks aren't having a banner year; notably, two large pharmaceutical companies recently plunged to 52-week lows 
Via MarketBeat
News headline image
Celldex Makes A Bullish Move As It Looks To Take On Regeneron, Sanofi ↗
The company is looking to take on Regeneron and Sanofi's Dupixent in skin diseases. 
Via Investor's Business Daily
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
42 43 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.